Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hangzhou
Clinical trial register · China

Clinical Trials in Hangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 09 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine373 Zhejiang University101 First Affiliated Hospital of Zhejiang University100 AstraZeneca74 Zhejiang Cancer Hospital65
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Hangzhou

1819 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Sanofi
Phase 2/3
1,856
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanchang
2022-08-22
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
348
Fuzhou, Dongguan, Guangdong, Zhengzhou, Wuhan, Jinan, Hangzhou
2022-08-09
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Beijing, Changchun, Changzhou, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou
2022-08-05
Recruiting
He Huang
Phase 1
29
Hangzhou
2022-08-04
Recruiting
He Huang
Phase 1
29
Hangzhou
2022-08-04
Recruiting
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
442
Hefei, Beijing, Guangzhou, Hangzhou, Harbin, Wuhan, Changsha, Zhengzhou
2022-08-03
Recruiting
Zhejiang Cancer Hospital
Phase 2
41
Hangzhou, Jiaxing, Jinhua, Lishui, Ningbo, Quzhou
2022-08-01
Recruiting
ZR2 Sequential Immunochemotherapy for Newly Treated MCL
NCT05992597Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma
Zhejiang Cancer Hospital
Phase 2
48
Hangzhou
2022-08-01
Active, closed
AstraZeneca
Phase 4
43
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2022-07-29
Recruiting
Janssen Research & Development, LLC
Phase 1/2
225
Dalian, Guangzhou, Hangzhou, Wuhan
2022-07-29
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
125
Hangzhou
2022-07-22
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
DrugsPirtobrutinib·Ibrutinib
Loxo Oncology, Inc.
Phase 3
737
Changsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai
2022-07-22
Active, closed
Gilead Sciences
Phase 3
623
Beijing, Changsha, Chengdu, Chongqing, Deyang, Guangzhou, Hangzhou, Harbin
2022-07-20
Active, closed
Hoffmann-La Roche
Phase 3
922
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou
2022-07-18
Active, closed
AstraZeneca
Phase 2
72
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2022-07-13
Recruiting
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
NCT05200260Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
DrugsOlaparib·Bevacizumab
Shanghai Gynecologic Oncology Group
Phase 2
220
Foshan, Guangzhou, Hangzhou, Hefei, Shanghai
2022-07-13
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
1,576
Hangzhou
2022-07-10
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
2,413
Hangzhou
2022-07-10
Recruiting
The Third Affiliated hospital of Zhejiang Chinese Medical University
Not applicable
120
Hangzhou
2022-07-02
Recruiting
Zhejiang University
Observational
5,000
Hangzhou
2022-07-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
100
Hangzhou
2022-07-01
Active, closed
Sanofi
Phase 3
531
Beijing, Changsha, Guangzhou, Hangzhou, Nanchang, Nanning, Qingdao, Shenyang
2022-06-23
Active, closed
Beckman Coulter, Inc.
Observational
2,200
Beijing, Chengdu, Hangzhou
2022-06-23
Active, closed
Akeso
Phase 3
636
Beijing, Guiyang, Wuhan, Changsha, Shanghai, Chengdu, Hangzhou
2022-06-21
Active, closed
Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
NCT05363800Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
74
Zhengzhou, Shengyang, Hangzhou
2022-06-17
Active, closed
Hoffmann-La Roche
Phase 3
60
Beijing, Changsha, Chongqing, Fuzhou, Hangzhou, Hefei, Linyi, Nanjing
2022-06-14
Active, closed
Ruijin Hospital
Not applicable
200
Changsha, Beijing, Dongyang, Fuyang, Hangzhou, Lishui, Nanchang, Nanjin
2022-06-08
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1
398
Guangzhou, Zhengzhou, Wuhan, Shanghai, Hangzhou
2022-06-07
Recruiting
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Phase 1
288
Beijing, Changsha, Ganzhou, Hangzhou, Hanzhou, Linyi, Nanjing
2022-06-01
By invitation
Qiu Guoqin
Phase 1/2
30
Hangzhou
2022-06-01
Recruiting
Dimerix Bioscience Pty Ltd
Phase 3
286
Baotou, Beijing, Chengdu, Guangzhou, Hangzhou, Hohhot, Jinan, Nanchang
2022-05-30
Recruiting
Zhuhai Yufan Biotechnologies Co., Ltd
Phase 1/2
267
Zhengzhou, Chengdu, Hangzhou, Beijing
2022-05-30
Recruiting
A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
NCT05518253Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer
Weijia Fang, MD
Phase 1
30
Hangzhou
2022-05-30
Active, closed
Biotheus Inc.
Phase 2
99
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Harbin, Jinan, Nanchang
2022-05-27
Active, closed
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
NCT05297890Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
DrugLorlatinib
CStone Pharmaceuticals
Phase 2
70
Guangzhou, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou
2022-05-27
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
82
Bengbu, Guangzhou, Guilin, Wuhan, Yueyang, Changchun, Hangzhou
2022-05-20
Active, closed
A Study of AL8326 in Non-Small Cell Lung Cancer
NCT06794957Non-small Cell Lung Cancer
DrugAL8326
Advenchen Laboratories, LLC
Phase 1
158
Bengbu, Hefei, Xuancheng, Anyang, Zhengzhou, Wuhan, Nanjing, Hangzhou
2022-05-19
Recruiting
A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
NCT06173076Autoimmune Encephalitis, Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Shen Chun-Hong
Observational
60
Hangzhou
2022-05-18
Active, closed
Istituto Giannina Gaslini
Observational
272
Hangzhou
2022-05-18
Active, closed
AstraZeneca
Phase 3
644
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2022-05-16
Recruiting
Sun Yat-sen University
Phase 2
280
Changchun, Chengdu, Dongguan, Dongyang, Foshan, Guangzhou, Hangzhou, Jiangmen
2022-05-06
Active, closed
Akeso
Phase 1/2
154
Hangzhou
2022-05-04
Recruiting
APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
NCT04657861Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Zhejiang University
Early Phase 1
36
Hangzhou
2022-05-03
Recruiting
Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen
NCT05731258Breast Cancer, Liposomal Doxorubicin, Efficacy, Safety
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
150
Hangzhou
2022-05-01
Recruiting
Peking Union Medical College Hospital
Observational
20,000
Beijing, Chongqing, Shenzhen, Changsha, Nanjing, Hangzhou
2022-04-29
By invitation
AstraZeneca
Phase 3
214
Beijing, Changsha, Hangzhou, Nanjing, Shanghai, Shenyang, Wenzhou, Xi'an
2022-04-19
Recruiting
Sun Yat-sen University
Phase 3
212
Guangzhou, Beijing, Chengdu, Fuzhou, Guiyang, Hangzhou, Nanchang, Nanning
2022-04-01
Active, closed
AstraZeneca
Phase 3
760
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou
2022-03-28
Active, closed
AstraZeneca
Phase 3
1,035
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jiaxing
2022-03-25
Recruiting
Clinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma
NCT06746480Advanced Intrahepatic Cholangiocarcinoma
CNBG-Virogin Biotech (Shanghai) Ltd.
Phase 2
33
Hangzhou
2022-03-19
Active, closed
Hoffmann-La Roche
Phase 2
58
Beijing, Guangzhou, Hangzhou, Shanghai, Shenyang
2022-03-18
Recruiting
The Third Affiliated hospital of Zhejiang Chinese Medical University
Not applicable
84
Hangzhou
2022-03-16
Recruiting
Zhejiang Cancer Hospital
Observational
100
Hangzhou
2022-03-16
Active, closed
Pfizer
Phase 1/2
235
Changchun, Shanghai, Chengdu, Tianjin, Hangzhou
2022-03-14
Recruiting
Hangzhou Valgen Medtech Co., Ltd
Not applicable
120
Hangzhou
2022-03-12
Recruiting
Clinical Application Strategies of Maxillary Sinus Buccal Bony Window
NCT05315791Sinus Floor Augmentation, Maxillary Sinus
The Dental Hospital of Zhejiang University School of Medicine
Not applicable
60
Hangzhou
2022-03-10
Recruiting
Janssen Research & Development, LLC
Phase 4
295
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an
2022-03-09
Active, closed
Daiichi Sankyo
Phase 2
187
Changchun, Changsha, Chengdu, Guangdong, Hangzhou, Linyi, Shanghai, Wuhan
2022-03-09
Recruiting
RemeGen Co., Ltd.
Phase 1/2
135
Shanghai, Hangzhou
2022-03-03
Recruiting
Changhai Hospital
Not applicable
150
Beijing, Guangzhou, Wuhan, Xi'an, Shanghai, Chengdu, Hangzhou
2022-03-01
Active, closed
Janssen Research & Development, LLC
Phase 2
151
Beijing, Chengdu, Hangzhou, Shanghai
2022-03-01
Active, closed
AstraZeneca
Phase 3
390
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2022-02-21
Recruiting
Zhejiang University
Phase 1
72
Hangzhou, Zhengzhou
2022-02-21
Recruiting
Retrospective Study of Brachytherapy
NCT05242861Brachytherapy, Uterine Cervical Neoplasms, Uterine Neoplasms, Vulvar Cancer
Zhejiang Cancer Hospital
Observational
300
Hangzhou
2022-02-20
Recruiting
Sanofi
Phase 3
284
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Shanghai, Suzhou, Wuhan
2022-02-15
Active, closed
AstraZeneca
Phase 3
363
Beijing, Bengbu, Chengdu, Guangzhou, Haikou, Hangzhou, Jinan, Jining
2022-02-15
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
96
Beijing, Nanchang, Jinan, Chengdu, Tianjin, Hangzhou
2022-02-14
Recruiting
Takeda
Phase 3
120
Beijing, Zhengzhou, Shanghai, Hangzhou
2022-02-10
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
446
Hangzhou
2022-02-08
Active, closed
AstraZeneca
Phase 3
1,051
Anyang, Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Hefei, Kunming
2022-02-07
By invitation
UCB Biopharma SRL
Phase 3
300
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming
2022-02-03
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
100
Hangzhou
2022-01-31
Recruiting
PROfiling Based Endometrial Cancer Adjuvant Therapy
NCT05179447Endometrial Cancer Stage I, Endometrial Cancer Stage II
Women's Hospital School Of Medicine Zhejiang University
Not applicable
590
Wuhan, Jinan, Hangzhou, Beijing, Changsha, Guangzhou, Ningbo, Shanghai
2022-01-24
Active, closed
Xiangyun Zong
Not applicable
258
Shanghai, Hangzhou
2022-01-03
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
500
Hangzhou
2022-01-01
By invitation
The Affiliated Hospital of Hangzhou Normal University
Not applicable
160
Hangzhou
2022-01-01
Recruiting
The Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma
NCT05323929Early Gastric Cancer, Endoscopic Submucosal Dissection
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
200
Hangzhou
2022-01-01
Recruiting
The First Affiliated Hospital of Zhejiang Chinese Medical University
Observational
80
Hangzhou
2022-01-01
Recruiting
Zhejiang Cancer Hospital
Phase 4
606
Hangzhou
2022-01-01
Recruiting
ET-SPACE Whole-Body Infrared Hyperthermia in Patients With Advanced Solid Tumors
NCT07793214Advanced Solid Tumors, Advanced Solid Tumors Cancer
Zhejiang Hospital
Observational
500
Hangzhou
2022-01-01
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
DrugLorlatinib
Pfizer
Phase 4
76
Hefei, Beijing, Fuzhou, Guangzhou, Changsha, Nanjing, Changchun, Hangzhou
2021-12-28
Recruiting
Novartis Pharmaceuticals
Phase 1/2
34
Hangzhou, Beijing, Shanghai, Tianjin
2021-12-27
Active, closed
Crizotinib Continuation Clinical Study
NCT05160922NSCLC, ALCL, IMT
DrugCrizotinib
Pfizer
Phase 4
27
Beijing, Fuzhou, Guangzhou, Changchun, Wuhou District, Hangzhou, Shanghai
2021-12-27
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
45
Guilin, Guiyang, Wuhan, Changsha, Shanghai, Chengdu, Hangzhou
2021-12-22
Recruiting
Merck Sharp & Dohme LLC
Phase 1
830
Beijing, Fuzhou, Guangzhou, Wuhan, Changchun, Shanghai, Hangzhou
2021-12-17
Active, closed
GlaxoSmithKline
Phase 2
366
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming, Shanghai
2021-12-14
Active, closed
Novartis Pharmaceuticals
Phase 3
1,007
Wuhan, Nanjing, Yinchuan, Taiyuan, Hangzhou, Wenzhou, Beijing, Shanghai
2021-12-13
Recruiting
A Clinical Study on TIL for the Treatment of Advanced Solid Tumors
NCT05087745Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects, Effects of Immunotherapy
DrugTumor Infiltrating Lymphocytes
Shanghai Juncell Therapeutics
Early Phase 1
50
Hangzhou
2021-12-10
Recruiting
Idebenone for the Preventive Treatment of Migraine
NCT04151472Migraine Disorders, Headache Disorders
DrugIdebenone
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
180
Hangzhou
2021-12-08
Recruiting
UCB Biopharma SRL
Phase 3
350
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming
2021-12-07
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
27
Hangzhou
2021-12-02
Active, closed
Hoffmann-La Roche
Phase 3
49
Guangzhou, Harbin, Wuhan, Jinan, Hangzhou, Beijing, Changchun, Changsha
2021-12-01
Active, closed
Womed
Not applicable
160
Guangzhou, Hangzhou, Shanghai
2021-11-29
Recruiting
Therapy Evaluation in Patients With Minor Stroke and Large Vessel Occlusion
NCT06633809Stroke, Acute, Cerebrovascular Disorders, Brain Diseases, Central Nervous System Diseases
Sir Run Run Shaw Hospital
Observational
200
Hangzhou
2021-11-22
Recruiting
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
NCT04662294Acute Myeloid Leukemia, Non-hodgkin's Lymphoma, Multiple Myeloma
Zhejiang University
Early Phase 1
108
Hangzhou
2021-11-18
Active, closed
Hoffmann-La Roche
Phase 3
41
Beijing, Hangzhou
2021-11-17
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Huizhou
2021-11-17
Recruiting
Immune Score Based Radiomics in Nasopharyngeal Carcinoma
NCT05126160Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Observational
494
Wuhan, Ningbo, Wenzhou, Hangzhou
2021-11-05
Recruiting
Akeso
Phase 1/2
198
Hangzhou
2021-11-03
Recruiting
Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting
NCT04694248Deep Vein Thrombosis, Iliac Vein Thrombosis, Iliac Vein Obstruction, Iliac Vein Stenosis
DrugsRivaroxaban·Aspirin
First Affiliated Hospital of Zhejiang University
Not applicable
172
Hangzhou
2021-11-03
Recruiting
Chinese Longitudinal and Systematic Study of Bioplar Disorder
NCT05480150Major Depressive Disorder, Bipolar Disorder, Mixed, Affective; Disorder, Organic
DrugsLurasidone·Quetiapine·Escitalopram
First Affiliated Hospital of Zhejiang University
Not applicable
10,000
Hangzhou
2021-11-01
Recruiting
The Osteoarticular Manifestations in Patients With Gitelman Syndrome
NCT06922370Gitelman Syndrome, CPPD - Calcium Pyrophosphate Deposition Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
120
Hangzhou
2021-11-01
Active, closed
AstraZeneca
Phase 3
454
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan
2021-10-28
Active, closed
AstraZeneca
Phase 3
732
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou
2021-10-18
Active, closed
Janssen Research & Development, LLC
Phase 3
587
Beijing, Changchun, Changshashi, Chaoyang District, Chengdu, Fuzhou, Guangzhou, Hangzhou
2021-10-14
Active, closed
Merck Sharp & Dohme LLC
Phase 1
45
Beijing, Guangzhou, Nanjing, Tianjin, Hangzhou
2021-10-13
Active, closed
Gilead Sciences
Phase 2
53
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanjing
2021-10-12
Active, closed
Haihe Biopharma Co., Ltd.
Phase 2
93
Beijing, Chongqing, Guangdong, Haikou, Hainan, Hangzhou, Harbin, Hubei
2021-10-11
Recruiting
The Dental Hospital of Zhejiang University School of Medicine
Not applicable
48
Hangzhou
2021-09-27
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
333
Fuzhou, Wuhan, Changchun, Hangzhou, Beijing
2021-09-22
Active, closed
Loxo Oncology, Inc.
Phase 3
600
Beijing, Changsha, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Hengyang
2021-09-20
Recruiting
Gao's Triple Eversion Carotid Endarterectomy
NCT06722222Carotid Artery Stenosis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
11
Hangzhou
2021-09-17
Recruiting
Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors
NCT04933669Progression-free Survival, Gastrointestinal Stromal Tumor, Neoadjuvant
DrugImatinib
First Affiliated Hospital of Zhejiang University
Phase 2
122
Hangzhou
2021-09-07
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
50
Hangzhou
2021-09-06
Recruiting
Sir Run Run Shaw Hospital
Early Phase 1
10
Hangzhou
2021-09-05
Active, closed
Abbisko Therapeutics Co, Ltd
Phase 1
102
Chongqing, Fuzhou, Ganzhou, Hangzhou, Harbin, Hefei, Mianyang, Nanjing
2021-08-31
Active, closed
PRL3-Zumab in Patients With Advanced Solid Tumors
NCT07541001Advanced Malignant Solid Tumor
DrugPRL3-ZUMAB
Intra-IMMUSG Pte Ltd
Phase 2
60
Hangzhou
2021-08-30
Active, closed
Akeso
Phase 3
445
Hangzhou, Hefei, Shanghai
2021-08-27
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Zhengzhou, Changsha, Nanchang, Changchun, Shanghai, Chengdu, Hangzhou, Beijing
2021-08-27
Active, closed
Akeso
Phase 1/2
68
Hangzhou
2021-08-13
Recruiting
Zhejiang Cancer Hospital
Phase 3
455
Hangzhou, Jinhua, Lishui, Ningbo, Taizhou, Wanzhou
2021-08-02
By invitation
Chinese Academy of Medical Sciences
Phase 3
606
Beijing, Changsha, Chendu, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2021-08-01
Active, closed
GlaxoSmithKline
Phase 3
72
Beijing, Changchun, Guangzhou, Hangzhou, Jinan, Nanjing, Shenyang, Suzhou
2021-07-28
Active, closed
Dizal Pharmaceuticals
Phase 2
104
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Haikou, Hangzhou
2021-07-19
Active, closed
Evolut PRO China Clinical Study
NCT04982588Severe, Symptomatic Aortic Stenosis
Medtronic Cardiovascular
Not applicable
52
Beijing, Chengdu, Hangzhou
2021-07-17
Recruiting
Janssen Research & Development, LLC
Phase 3
199
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan
2021-07-15
Recruiting
International Headache Registry Study
NCT05418218Headache Disorders, Primary, Headache Disorders, Secondary, Migraine, Tension-Type Headache
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
200,000
Hangzhou
2021-07-12
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
50
Hangzhou
2021-07-02
Recruiting
Boehringer Ingelheim
Phase 1
554
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai
2021-07-02
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
19
Hangzhou
2021-07-01
Not yet open
Diabetes Complications and the Risk of Cardiovascular and Cerebrovascular Diseases
NCT04983277Diabetes Complications, Cardiovascular Diseases, Cerebrovascular Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
3,000
Hangzhou
2021-07
Active, closed
Hoffmann-La Roche
Phase 3
142
Hangzhou, Beijing, Chengdu, Fuzhou, Guangzhou, Shanghai, Wuhan, Xi'an
2021-06-25
Active, closed
Hangzhou Endonom Medtech Co., Ltd.
Not applicable
88
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Kunming
2021-06-07
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
90
Hangzhou
2021-06-02
Recruiting
Clinical Study for AL-CM
NCT04924998Immunoglobulin Light Amyloidosis Cardiomyopathy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
400
Hangzhou
2021-06-01
Recruiting
Zhejiang Cancer Hospital
Observational
100,000
Hangzhou
2021-06-01
Recruiting
Clinical Study of ATTR-CM
NCT04935021Transthyroxine Amyloidosis Cardiomyopathy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
100
Hangzhou
2021-06-01
Recruiting
Clinical Study of Endocardial Myocardial Biopsy
NCT05718128Myocarditis, Cardiomyopathies, Heart Failure, Cardiac Tumor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
100
Hangzhou
2021-06-01
Recruiting
Ascentage Pharma Group Inc.
Phase 1/2
95
Guangzhou, Hangzhou, Shanghai
2021-05-26
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,100
Hangzhou
2021-05-20
Recruiting
Janssen Research & Development, LLC
Phase 1/2
420
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing
2021-05-19
Active, closed
Hoffmann-La Roche
Observational
800
Changsha, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Taiyuan
2021-05-10
Active, closed
AstraZeneca
Phase 3
893
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2021-05-10
Recruiting
Study of Tenofovir Alafenamide in HBV-Infected Pregnant Women
NCT05853718Chronic Hepatitis b, Tenofovir Alafenamide Fumarate
DrugTenofovir Alafenamide
First People's Hospital of Hangzhou
Phase 4
50
Hangzhou
2021-05-06
By invitation
Hangzhou Valgen Medtech Co., Ltd
Not applicable
120
Hangzhou
2021-05-04
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,000
Hangzhou
2021-05-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
2,000
Hangzhou
2021-05-01
Recruiting
Women's Hospital School Of Medicine Zhejiang University
Not applicable
400
Hangzhou
2021-05-01
Active, closed
AstraZeneca
Phase 3
1,157
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Guangzhou, Hangzhou
2021-04-26
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,000
Hangzhou
2021-04-20
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
10
Hangzhou
2021-04-19
Active, closed
Jia Fan
Phase 3
501
Shanghai, Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei
2021-04-19
Recruiting
Ruijin Hospital
Not applicable
710
Lanzhou, Shenyang, Jinan, Chengdu, Hangzhou, Shanghai
2021-04-08
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
289
Hangzhou
2021-04-01
Recruiting
The Safety and Efficiency of Endovascular Treatment of Acute or Subacute Thromboembolic Occlusions of Lower Extremity.
NCT04861506Thromboembolic Disease, Lower Extremity Problem, Endovascular Treatment, Safety Issues
First People's Hospital of Hangzhou
Observational
400
Hangzhou
2021-04-01
Active, closed
Karyopharm Therapeutics Inc
Phase 2
112
Beijing, Wuhan, Nantong, Suzhou, Changchun, Hangzhou
2021-03-17
Active, closed
Hoffmann-La Roche
Phase 3
342
Anhui, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2021-03-12
Recruiting
Shanghai Henlius Biotech
Phase 2/3
568
Guangzhou, Hangzhou, Linyi, Shanghai
2021-03-10
Active, closed
Zhejiang University
Phase 1
21
Hangzhou
2021-03-10
Active, closed
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
NCT04279847Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm
DrugRuxolitinib
Incyte Corporation
Phase 1
140
Beijing, Guangzhou, Hangzhou, Zhengzhou
2021-02-23
Active, closed
Bioverativ, a Sanofi company
Phase 3
261
Beijing, Guangzhou, Hangzhou, Jinan, Kunming, Lanzhou, Suzhou
2021-02-23
Active, closed
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
277
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Nanjing, Shanghai
2021-02-02
Active, closed
A Study of Endovascular Treatment of Femoropopliteal Arterial Occlusive Lesion With Drug-Coated Balloon
NCT04826705Drug-coated Balloon, Femoropopliteal Artery Occlusion, Angioplasty
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology
Observational
2,000
Wuhan, Beijing, Chengdu, Hangzhou, Qingdao, Shanghai, Suzhou
2021-02-01
Recruiting
Janssen Research & Development, LLC
Phase 2
510
Beijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Xi'an
2021-02-01
Not yet open
Zhejiang University
Early Phase 1
144
Hangzhou
2021-01-15
Not yet open
Zhejiang University
Early Phase 1
36
Hangzhou
2021-01-15
Active, closed
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
59
Beijing, Fuzhou, Guanzhou, Zhengzhou, Nanjing, Shanghai, Tianjin, Hangzhou
2021-01-13
Recruiting
China Longitudinal Aging and Cognitive Impairment Study
NCT05468905Aging, Mild Cognitive Impairment, Alzheimer Disease, Neurodegeneration
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
4,000
Hangzhou, Lishui
2021-01-10
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
294
Hangzhou
2021-01-01
Not yet open
Zhejiang University
Early Phase 1
36
Hangzhou
2021-01-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
84
Hefei, Yantai, Shanghai, Hangzhou
2021-01-01
Not yet open
A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
NCT04670055Relapse Multiple Myeloma, Refractory Multiple Myeloma
Zhejiang University
Early Phase 1
50
Hangzhou
2021-01-01
Active, closed
Novartis Pharmaceuticals
Observational
78
Fuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Kunming, Hangzhou, Beijing
2020-12-31
Not yet open
Zhejiang University
Early Phase 1
50
Hangzhou
2020-12-31
Recruiting
Prospective Cohort Study of Intracerebral Hemorrhage
NCT04707105Intracerebral Hemorrhage
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
856
Hangzhou
2020-12-29
Active, closed
Hangzhou Endonom Medtech Co., Ltd.
Not applicable
120
Beijing, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Hefei
2020-12-25
Active, closed
Daiichi Sankyo
Phase 3
605
Beijing, Changsha, Hangzhou, Hangzou, Heilongjiang, Henan, Hubei, Nanjing
2020-12-21
Active, closed
AstraZeneca
Phase 3
358
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang
2020-12-16
Active, closed
Janssen Research & Development, LLC
Phase 3
518
Beijing, Changchun, Changsha, Changsha Shi, Chengdu, Chongqing, Guangzhou, Hangzhou
2020-12-07
Active, closed
Daiichi Sankyo
Phase 3
1,600
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2020-12-04
Recruiting
Zhejiang University
Phase 2
40
Hangzhou
2020-12-03
Recruiting
Zhejiang University
Not applicable
1,000
Hangzhou
2020-12-01
Recruiting
Durg Coated Balloon Angioplasty in Infrapopliteal Lesions
NCT05620095Arteriosclerosis, Peripheral Artery Disease, Chronic Limb Threatening Ischemia
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology
Observational
1,000
Beijing, Wuhan, Suzhou, Qingdao, Shanghai, Chengdu, Hangzhou
2020-12-01
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
42
Hangzhou
2020-11-23
Active, closed
Gilead Sciences
Phase 3
331
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan
2020-11-23
Not yet open
CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
NCT04609241Relapsed and/or Refractory Acute Lymphoblastic Leukemia, Relapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma
Zhejiang University
Early Phase 1
72
Hangzhou
2020-11-15
Not yet open
Zhejiang University
Early Phase 1
36
Hangzhou
2020-11-15
Active, closed
Hecheng Li M.D., Ph.D
Phase 3
244
Shanghai, Hangzhou, Ningbo
2020-11-10
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
47
Hefei, Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Tianjin, Hangzhou
2020-11-04
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
281
Beijing, Guangzhou, Hangzhou, Shanghai, Suzhou, Wenzhou, Wuhan
2020-11-03
Active, closed
Gilead Sciences
Phase 2
80
Beijing, Shenyang, Hangzhou, Changchun, Changsha, Chengdu, Chongqing, Guangzhou
2020-10-23
Active, closed
Hoffmann-La Roche
Phase 3
210
Beijing, Guangzhou, Hangzhou, Nanjing, Nantong, Shanghai, Wuhan
2020-10-08
Active, closed
Acerta Pharma BV
Phase 3
611
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang
2020-10-08
Active, closed
GlaxoSmithKline
Phase 3
302
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Jiangsu, Nanchang, Shenyang
2020-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
1,074
Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2020-09-30
Active, closed
Daiichi Sankyo Co., Ltd.
Phase 3
40
Beijing, Guangzhou, Hangzhou, Shanghai
2020-09-25
Active, closed
Janssen Research & Development, LLC
Phase 3
696
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Ningbo
2020-09-23
Recruiting
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT04557449Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer)
DrugAtirmociclib
Pfizer
Phase 1/2
430
Beijing, Zhengzhou, Wuhan, Xi’an, Hangzhou
2020-09-23
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2/3
260
Hangzhou
2020-09-20
Active, closed
Janssen Research & Development, LLC
Phase 2
194
Beijing, Chengdu, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Xi'an
2020-09-17
Recruiting
Multi-omics Research of Idopathic Normal Pressure Hydrocephalus (iNPH)
NCT04998175Idiopathic Normal Pressure Hydrocephalus
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
40
Hangzhou
2020-09-15
Active, closed
Karyopharm Therapeutics Inc
Phase 2/3
501
Nanjing, Suzhou, Huangpu, Xuhui, Chengdu, Hangzhou
2020-09-03
Active, closed
First Affiliated Hospital of Zhejiang University
Phase 3
232
Changsha, Chongqing, Hangzhou, Nanjing, Ningbo, Suzhou
2020-09-01
Recruiting
MR Microstructural Imaging for Prostate Cancer Diagnosis
NCT07249281Prostate Cancer, Diffusion MRI
First Affiliated Hospital of Zhejiang University
Observational
2,000
Beijing, Zhengzhou, Nanjing, Dalian, Hangzhou
2020-09-01
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
125
Beijing, Guangzhou, Hangzhou, Wenzhou, Wuhan
2020-08-25
Recruiting
Clinical Study of Impact of Different Pacing Site in Patients
NCT04931550Bradyarrhythmias, Heart Failure, Pacemaker
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
600
Hangzhou
2020-08-01
Recruiting
RFA Plus Carrizumab vs Carrizumab Alone for HCC
NCT04150744Tumor Immunity, Immunosuppression, Radiofrequency Ablation
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
120
Hangzhou
2020-08-01
Recruiting
InxMed (Shanghai) Co., Ltd.
Phase 1/2
150
Anyang, Beijing, Changsha, Fuzhou, Hangzhou, Tianjin, Zhengzhou
2020-07-27
Recruiting
SMART Watch Facilitated Early Discharge in Patients Undergoing Transcatheter Aortic Valve Replacement
NCT04454177Aortic Stenosis, Valvular Heart Disease, Transcatheter Aortic Valve Replacement
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
100
Hangzhou
2020-07-15
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
537
Beijing, Guangzhou, Zhengzhou, Nanjing, Shanghai, Chengdu, Hangzhou
2020-07-14
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
10,000
Hangzhou, Beijing, Chongqing, Fujian, Gansu, Guangdong, Guangxi, Guizhou
2020-07-08
Active, closed
Sanofi
Phase 3
337
Hangzhou, Nanchang, Shanghai, Shenyang, Tianjin
2020-06-16
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,872
Hangzhou, Beijing, Guangdong, Huzhou, Jinan, Jinhua, Kunming, Nanchang
2020-05-29
Recruiting
xuexin he
Not applicable
183
Hangzhou, Jiaxing, Lishui
2020-05-09
Active, closed
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
NCT03932331Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia
DrugAcalabrutinib
AstraZeneca
Phase 1/2
105
Beijing, Changchun, Changsha, Changzhou, Chengdu, Fuzhou, Haikou, Hangzhou
2020-04-29
Active, closed
Xynomic Pharmaceuticals, Inc.
Phase 2
87
Beijing, Changchun, Chengdu, Dalian, Fuzhou, Guangzhou, Hainan, Hangzhou
2020-04-22
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
60
Guangzhou, Chengdu, Hangzhou
2020-04-17
Active, closed
GlaxoSmithKline
Phase 3
325
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Nanchang, Shenzhen, Tianjin
2020-04-02
Active, closed
Eli Lilly and Company
Phase 2
77
Beijing, Guangzhou, Changsha, Changchun, Jinan, Shanghai, Tianjin, Hangzhou
2020-03-16
Recruiting
Amgen
Phase 1
479
Beijing, Guangzhou, Nanchang, Shanghai, Hangzhou, Nanjing, Wenzhou
2020-03-04
Recruiting
Sun Yat-sen University
Phase 3
212
Guangzhou, Beijing, Chengdu, Fuzhou, Guiyang, Hangzhou, Nanchang, Nanning
2020-03-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,850
Hangzhou
2020-02-20
Active, closed
Hoffmann-La Roche
Phase 2/3
325
Beijing, Changchun, Chongqing, Fujian, Guangzhou, Hangzhou, Harbin, Shanghai
2020-01-29
Recruiting
Xynomic Pharmaceuticals, Inc.
Phase 2
170
Beijing, Chengdu, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Lanzhou
2020-01-20
Active, closed
AstraZeneca
Phase 3
155
Beijing, Changchun, Changsha, Changzhou, Guangzhou, Guiyang, Hangzhou, Hefei
2020-01-20
Recruiting
He Huang
Early Phase 1
72
Hangzhou
2020-01-08
Active, closed
Xynomic Pharmaceuticals, Inc.
Phase 1/2
12
Beijing, Hangzhou, Tianjin, Xuzhou
2020-01-08
Recruiting
Fudan University
Phase 4
800
Fuzhou, Zhengzhou, Wuhan, Hohhot, Shanghai, Shanxi, Hangzhou, Beijing
2020-01-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,200
Hangzhou
2020-01-01
Active, closed
Ruijin Hospital
Phase 2/3
580
Baoding, Beijing, Changsha, Changzhi, Chengdu, Guiyang, Haikou, Hangzhou
2019-12-18
Active, closed
Bristol-Myers Squibb
Phase 3
461
Beijing, Fuzhou, Hubei Sheng, Changsha, Shanghai, Chengdu, Hangzhou
2019-11-05
Recruiting
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
NCT03983226Ovarian Cancer Recurrent, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
DrugNiraparib
Shanghai Gynecologic Oncology Group
Phase 2
167
Shanghai, Guangzhou, Hangzhou
2019-10-18
Active, closed
SyncAV Post-Market Trial
NCT04100148Congestive Heart Failure
Abbott Medical Devices
Not applicable
1,686
Tianjin, Xi'an, Hangzhou
2019-10-03
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Not applicable
690
Hefei, Nanyang, Nantong, Xuzhou, Yancheng, Jinan, Shanghai, Hangzhou
2019-10-01
Active, closed
Astellas (Beijing) Pharmaceutical R&D Co., Ltd.
Phase 3
180
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Nanchang, Shanghai
2019-09-11
Active, closed
Janssen Research & Development, LLC
Phase 1
701
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan
2019-09-04
Active, closed
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
NCT06239155Advanced Solid Tumors, Hepatocellular Carcinoma
DrugAST-3424
Ascentawits Pharmaceuticals, Ltd
Phase 1/2
51
Guangzhou, Zhengzhou, Nanjing, Shenyang, Shanghai, Hangzhou
2019-09-03
Active, closed
Westlake Precision Birth Cohort
NCT04060056Diabetes, Gestational, Pregnancy in Diabetics, Intrauterine Hyperglycemia
Westlake University
Not applicable
2,001
Hangzhou
2019-08-30
Active, closed
Janssen Research & Development, LLC
Phase 2/3
118
Beijing, Changchun, Chengdu, Guangzhou, Haikou, Hangzhou, Lanzhou, Nanjing
2019-08-15
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
DrugLuspatercept
Celgene
Phase 3
665
Beijing, Guangzhou, Shanghai, Chengdu, Tianjin, Hangzhou
2019-08-12
Active, closed
Betta Pharmaceuticals Co., Ltd.
Phase 1
54
Hangzhou
2019-07-18
Active, closed
AstraZeneca
Phase 3
587
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Haikou, Hangzhou
2019-07-02
Recruiting
Transpacific TAVR Registry
NCT03826264Heart Valve Diseases, Aortic Valve Insufficiency
Duk-Woo Park, MD
Observational
10,000
Hangzhou
2019-06-15
Active, closed
Ascentage Pharma Group Inc.
Phase 1
74
Hefei, Zhengzhou, Wuhan, Tianjin, Hangzhou
2019-06-03
Active, closed
LEO Pharma
Phase 2
131
Guangzhou, Hangzhou, Shanghai, Xi'an
2019-05-29
Recruiting
APG-2449 in Patients With Advanced Solid Tumors
NCT03917043Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer
DrugAPG -2449
Ascentage Pharma Group Inc.
Phase 1
165
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Hangzhou
2019-05-27
Active, closed
AstraZeneca
Phase 3
810
Baoding, Beijing, Bengbu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin
2019-04-16
Recruiting
AstraZeneca
Phase 3
140
Beijing, Changsha, Chengdu, Chongqing, Hangzhou, Hefei, Shanghai
2019-04-02
Recruiting
Chinese University of Hong Kong
Phase 3
1,734
Xi'an, Shanghai, Tianjin, Hangzhou
2019-03-21
Active, closed
AstraZeneca
Phase 3
724
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou, Hefei, Jinan
2019-03-06
Recruiting
Women's Hospital School Of Medicine Zhejiang University
Phase 2
70
Hangzhou
2019-03-01
Active, closed
Acerta Pharma BV
Phase 3
984
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang
2019-02-25
Recruiting
Fudan University
Phase 3
1,006
Anqing, Hangzhou, Hefei, Nanchang, Shanghai, Wuhu
2019-01-01
Recruiting
Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule
NCT03785574Hydatidiform Mole, Gestational Trophoblastic Neoplasia
Women's Hospital School Of Medicine Zhejiang University
Not applicable
30
Hangzhou
2018-12-24
Active, closed
AstraZeneca
Phase 3
825
Beijing, Changsha, Changzhou, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2018-12-06
Active, closed
AstraZeneca
Phase 3
724
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2018-11-30
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
507
Fuzhou, Haikou, Zhengzhou, Changsha, Hengyang, Suzhou, Wuxi, Hangzhou
2018-11-28
Active, closed
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
DrugsPonatinib·Imatinib·Cytarabine·Methotrexate
Takeda
Phase 3
245
Zhengzhou, Suzhou, Changchun, Hangzhou, Tianjin
2018-10-04
Active, closed
AstraZeneca
Phase 3
1,246
Beijing, Changchun, Changsha, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan
2018-09-27
Active, closed
AstraZeneca
Phase 3
730
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou
2018-09-27
Active, closed
Hoffmann-La Roche
Phase 3
257
Beijing, Changchun, Chengdu, Fujian, Guangzhou, Hangzhou, Jinan, Shanghai
2018-08-16
Active, closed
AbbVie
Phase 3
1,533
Beijing, Guangzhou, Wuhan, Shenyang, Hangzhou, Changsha, Shanghai
2018-08-09
Active, closed
AstraZeneca
Phase 3
216
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Linhai
2018-07-19
Active, closed
Eli Lilly and Company
Phase 3
1,058
Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei
2018-07-18
Recruiting
Guangzhou Medical University
Observational
20,000
Hangzhou
2018-07-09
Active, closed
Beijing Friendship Hospital
Observational
2,000
Beijing, Guangzhou, Wuxi, Shanghai, Hangzhou
2018-06-29
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsFolinic acid·Zolbetuximab·Fluorouracil·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
565
Haerbin, Nanjing, Hangzhou, Beijing, Hefei, Xiamen, Zhengzhou
2018-06-21
Recruiting
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies
NCT04283006Relapsed and Refractory, Lymphoid Hematological Malignancies
He Huang
Early Phase 1
100
Hangzhou
2018-05-23
Active, closed
Centre Hospitalier Universitaire de Besancon
Not applicable
989
Hangzhou, Wenzhou
2018-05-03
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Tianjin, Beijing, Guangzhou, Changsha, Shanghai, Xi’an, Hangzhou, Ningbo
2018-04-24
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,409
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou
2018-04-13
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
480
Hangzhou
2018-04-02
Active, closed
Janssen Research & Development, LLC
Phase 3
629
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing
2018-03-23
Recruiting
Shanghai MicroPort CardioFlow Medtech Co., Ltd.
Not applicable
145
Beijing, Shanghai, Chengdu, Hangzhou
2018-01-31
Active, closed
Prognostic Impact of Coronary Microvascular Dysfunction After IVL Versus RA in Patients With Severe Coronary Calcification Undergoing PCI
NCT07699965Coronary Artery Calcification, Intravascular Lithotripsy, Coronary Microcirculation Dysfunction
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
590
Hangzhou
2018-01-01
Active, closed
Sanofi
Phase 3
475
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang
2017-12-07
Active, closed
AstraZeneca
Phase 3
1,324
Beijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Guangzhou, Hangzhou
2017-10-11
Active, closed
Hoffmann-La Roche
Phase 2/3
1,000
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing
2017-09-22
Active, closed
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
DrugsIvosidenib·Azacitidine
Institut de Recherches Internationales Servier
Phase 3
146
Zhengzhou, Chengdu, Beijing, Guangzhou, Hangzhou, Tianjin
2017-06-26
Recruiting
China Headache and Vertigo Registry Study
NCT04939922Headache Disorders, Primary, Headache Disorders, Secondary, Migraine, Tension-Type Headache
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
10,000
Hangzhou
2017-06-12
Active, closed
AstraZeneca
Phase 3
1,186
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
2017-06-01
Active, closed
Pfizer
Phase 3
296
Beijing, Changchun, Shanghai, Hangzhou, Guangzhou
2017-04-27
Active, closed
AstraZeneca
Phase 3
987
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Hangzhou, Hefei
2017-03-27
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
10,000
Hangzhou
2017-02-01
Recruiting
Clinical Outcomes Following Primary Intracerebral Hemorrhage
NCT06548737Stroke, Intracerebral Hemorrhage
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
25,000
Hangzhou
2016-10-27
Active, closed
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
NCT02864992Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
DrugTepotinib
EMD Serono Research & Development Institute, Inc.
Phase 2
337
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei
2016-09-13
Active, closed
Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)
NCT02859038Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Shanghai Gynecologic Oncology Group
Phase 3
489
Guangzhou, Shanghai, Hangzhou, Changsha
2016-08
Active, closed
Janssen Research & Development, LLC
Phase 1
751
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangong Apt/Yuncheng, Hangzhou, Hefei
2016-05-24
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
200,000
Hangzhou
2016-01-01
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai
2015-11-27
Active, closed
Hoffmann-La Roche
Phase 2
534
Harbin, Wuhan, Chengdu, Beijing, Guangzhou, Hangzhou, Shanghai, Shenzhen
2015-11-19
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Ningbo
2015-11-19
Active, closed
AstraZeneca
Phase 3
953
Beijing, Changchun, Chongqing, Guangzhou, Hangzhou, Shanghai, Ürümqi, Wuhan
2015-11-03
Active, closed
AstraZeneca
Phase 3
1,126
Beijing, Changchun, Changsha, Chongqing, Hangzhou, Nanjing, Shanghai, Shenyang
2015-11-02
Active, closed
AstraZeneca
Phase 3
682
Beijing, Changchun, Dalian, Guangzhou, Hangzhou, Kunming, Nanjing, Nanning
2015-10-21
Active, closed
MedImmune LLC
Phase 2
433
Hangzhou, Nanjing, Shanghai
2015-10-19
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
DrugsPanobinostat·Jakavi·Ruxolitinib
Novartis Pharmaceuticals
Phase 4
279
Hangzhou, Beijing
2015-03-05
Active, closed
Hoffmann-La Roche
Phase 3
154
Beijing, Changchun, Chengdu, Hangzhou, Harbin, Nanjing, Shanghai, Shenyang
2015-02-02
Recruiting
Zhejiang University
Observational
2,500
Hangzhou
2015-01-01
Active, closed
Eli Lilly and Company
Phase 3
453
Beijing, Changchun, Changzhou, Chengdu, Haikou, Hangzhou, Hefei, Nanning
2014-10-03
Active, closed
AstraZeneca
Phase 3
1,837
Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan, Nanjing
2014-04-22
Active, closed
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
DrugIbrutinib
Janssen Research & Development, LLC
Phase 3
539
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shanxi, Suzhou
2013-09-09
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2013-08-26
Recruiting
Ding Ke-Feng
Observational
55,000
Hangzhou, Beijing, Chengdu, Guangzhou, Shanghai
2013-01-01
Active, closed
Ding Ma
Not applicable
240
Wuhan, Jinan, Hangzhou
2012-11
Active, closed
Ding Ma
Phase 3
300
Wuhan, Jinan, Hangzhou
2012-11
Recruiting
Product Surveillance Registry
NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
Medtronic
Observational
100,000
Nanning, Chengdu, Beijing, Dalian, Guangzhou, Hangzhou, Harbin, Hefei
2012-01
Recruiting
Chinese Atrial Fibrillation Registry
NCT06987825Atrial Fibrillation (AF)
Beijing Anzhen Hospital
Observational
100,000
Beijing, Hangzhou
2011-08-01
Recruiting
Cognitive Impairment, Retinopathy, and Cerebrovascular Lesions in the Elderly
NCT03542734Cerebral Small Vessel Diseases, Retinopathy, Cognitive Dysfunction
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,000
Hangzhou
2010-01-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,000
Hangzhou
2009-06-30
Active, closed
Genentech, Inc.
Phase 2
378
Beijing, Changchun, Guangzhou, Hangzhou, Harbin, Nanjing, Shanghai
2008-10-16
Active, closed
First Affiliated Hospital of Zhejiang University
Observational
240
Hangzhou
2006-10-18
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,000
Hangzhou
2004-01-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,000
Hangzhou
2004-01-01
Recruiting
Genzyme, a Sanofi Company
Observational
9,000
Beijing, Hangzhou, Jinan, Nanjing, Shanghai
2001-07-31
Recruiting
The Jiaxing Birth Cohort in China
NCT03217656Childhood Obesity, Anemia, Pregnancy Complications, Pregnancy; Hypertension
Zhejiang University
Observational
500,000
Hangzhou
1999-01
Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
NCT00358943Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Genzyme, a Sanofi Company
Observational
12,000
Beijing, Guangzhou, Hangzhou, Nanjing, Shanghai
1991-04-01
Recruiting
Medtronic
Observational
20,000
Beijing, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
1983-01
Rows per page Showing 1501–1819 of 1819
Previous 2 3 4
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/hangzhou?page=4

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,819 of those studies with a site in Hangzhou.

How many clinical trials are recruiting in Hangzhou?

1,098 of the 1,819 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 309 have not yet opened recruitment, 370 are active but closed to new participants, and 42 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.